Considering the abundant immune cells and inflammatory factors in the bone marrow microenvironment, BMAs may also have the potential to release a significant amount of sIL6R and bind with IL6 to activate the trans-signaling in tumor cells. This evidence concerns the gene IL6R and neoplasm.